NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC — Stella

Recruiting

Back to Nanoliposomal Irinotecan trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment target

~30 participants

Started

April 2024

Primary completion

August 2026

Age range

18 Years and older

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov